{
  "pmcid": "8294837",
  "sha256": "4b6e2ad548ec24b43697d8923c0f90f78f387791f87a2ae55d1896cb974b0ee0",
  "timestamp_utc": "2025-11-09T22:57:49.346020+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.994842767295598,
    "reading_ease": 15.704140461215957,
    "word_count": 212
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Phase 2 Trial of Imlifidase for Desensitization in Kidney Transplantation"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "open-label, single-arm, phase 2 trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "Adult patients with a median calculated panel-reactive antibody (cPRA) of 99.83% were enrolled."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Imlifidase was administered intravenously to convert positive crossmatch tests to negative within 24 hours."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates imlifidase's efficacy in converting positive crossmatch tests to negative, enabling transplantation."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was crossmatch conversion, with secondary outcomes including donor-specific antibody levels, renal function, and safety."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 3,
        "evidence": "open-label"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "19 enrolled patients"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "18 received a full dose of imlifidase"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "89.5% achieving crossmatch conversion within 24 hours."
      },
      "Harms": {
        "score": 1,
        "evidence": "Seven adverse events were related to treatment, all mild to moderate."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "ClinicalTrials.gov NCT02790437."
      },
      "Funding": {
        "score": 1,
        "evidence": "The study was funded by Hansa Biopharma AB."
      }
    },
    "total_score": 20,
    "max_score": 25
  }
}